FDA Grants Accelerated Approval for Inovio's Voceryq to Treat RRP

The FDA has granted accelerated approval to Inovio Pharmaceuticals' Voceryq, a plasmid DNA-based immunotherapy, for adult recurrent respiratory papillomatosis (RRP). This treatment aims to reduce the need for repeated surgeries by generating an immune response against HPV types 6 and 11, offering a new therapeutic option for this rare airway disease.